133891-87-9

Usage

Uses

Used in Organic Synthesis:
1-Benzhydryl-3-methanesulfonyloxy-3-methylazetidine is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structure and reactivity allow for the formation of new chemical bonds and the synthesis of target compounds with desired properties.
Used in Pharmaceutical Research:
1-Benzhydryl-3-methanesulfonyloxy-3-methylazetidine is used as a starting material or building block in pharmaceutical research for the development of new drugs with specific biological activities. Its unique functional groups can be further modified or combined with other molecules to create novel drug candidates with potential therapeutic applications.
Used in the Construction of Complex Molecules:
1-Benzhydryl-3-methanesulfonyloxy-3-methylazetidine is used as a versatile building block for constructing more complex molecules with specific biological activities. Its unique structure and reactivity enable the formation of diverse molecular architectures, which can be further optimized for improved potency, selectivity, and pharmacokinetic properties.

Upstream product

• 40320-63-6 1-benzhydryl-3-methylazetidin-3-ol 
• 124-63-0 methanesulfonyl chloride 
• 133891-86-8 1-diphenylmethyl-3-hydroxy-3-methylazetidine hydrochloride 
• 40320-60-3 N-benzhydryl 3-azetidinone 

Downstream Products

• 133891-59-5 3-(aminoethyl)-1-(diphenylmethyl)-3-methylazetidine 
• 133891-58-4 1-(diphenylmethyl)-3-methyl-3-(((trifluoroacetyl)amino)methyl)azetidine 
• 1613720-40-3 6-(1-benzhydryl-3-methylazetidin-3-ylamino)-7-fluoro-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 1613720-21-0 6-(1-benzhydryl-3-methylazetidin-3-ylamino)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 1613720-22-1 6-(1-benzhydryl-3-methylazetidin-3-ylamino)-7-bromo-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 1613720-23-2 6-(1-benzhydryl-3-methylazetidin-3-ylamino)-4-methyl-7-phenyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 1613720-50-5 6-(1-benzhydryl-3-methylazetidin-3-ylamino)-4,7-dimethyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 1613721-08-6 (R)-6-(1-benzhydryl-3-methylazetidin-3-ylamino)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 133891-52-8 3-amino-1-(diphenylmethyl)-3-methylazetidine 
• 133891-61-9 3-(dimethylamino)-1-(diphenylmethyl)-3-methylazetidine 
• 133891-88-0 1-benzhydryl-3-methylazetidine-3-carbonitrile 
• 1613720-62-9 6-(1-benzhydryl-3-methylazetidin-3-yloxy)-4-methyl-7-trifluoromethyl-2-(2-trimethylsilanylethoxymethyl)-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 
• 1613720-30-1 2-[7-fluoro-6-(1-benzhydryl-3-methylazetidin-3-yloxy)-3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl]propionic acid ethyl ester 
• 1613720-05-0 2-[6-(1-benzhydryl-3-methylazetidin-3-yloxy)-3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl]propionic acid ethyl ester 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS

The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

Optimized protein kinase Cθ (PKCθ) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis

We previously demonstrated that selective inhibition of protein kinase Cθ (PKCθ) with triazinone 1 resulted in dose-dependent reduction of paw swelling in a mouse model of arthritis.1,2 However, a high concentration was required for efficacy, thus providing only a minimal safety window. Herein we describe a strategy to deliver safer compounds based on the hypothesis that optimization of potency in concert with good oral pharmacokinetic (PK) properties would enable in vivo efficacy at reduced exposures, resulting in an improved safety window. Ultimately, transformation of 1 yielded analogues that demonstrated excellent potency and PK properties and fully inhibited IL-2 production in an acute model. In spite of good exposure, twice-a-day treatment with 17l in the glucose-6-phosphate isomerase chronic in vivo mouse model of arthritis yielded only moderate efficacy. On the basis of the exposure achieved, we conclude that PKCθ inhibition alone is insufficient for complete efficacy in this rodent arthritis model.

ANTAGONISTS OF SNS SODIUM CHANNELS

Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R1 represents: (a) -L-A or -L' -A'

The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents

Several novel series of nitrile-containing fluoroquinolones with weakly basic amines are reported which have reduced potential for hERG (human ether-a-go-go gene) channel inhibition as measured by the dofetilide assay. The new fluoroquinolones are potent

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I) wherein A is formula (II), formula (III) or formula (IV), and B is formula (V), formula (VI), or formula (VII), can be used in a variety of applications including use as antibacterial agents.

7-Azetidinylquinolones as antibacterial agents. Synthesis and structure- activity relationships

A series of novel antibacterial quinolones and naphthyridones has been prepared which contain 7-azetidinyl substituents in place of the usual piperazine or aminopyrrolidine groups. These azetidinyl derivatives were evaluated for in vitro activity by deter

Quantitative structure-activity relationships of antibacterial agents, 7-heterocyclic amine substituted 1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acids

Quantitative structure-activity relationships (QSAR) of various 7-(3-substituted-azetidin-1-yl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro -4-oxoquinoline-3-carboxylic acids, 14-25, were studied to clarify the structural requirements for 3-substituted azetidi